Acadia Pharmaceuticals (ACAD)
Acadia Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
9.1M
Short interest
settlement 2026-10-15
4.6
Days to cover
+1.7 days vs prior
46.3%
Short share of volume
2026-11-02
6,765
Fails to deliver
settlement 2026-09-24
Wed 4 Nov
Next earnings
estimated date
-$657K
Insider flow, 90 days
0 buys, 4 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in ACAD is 9,094,151 shares, down 572,821 shares over the last month. Over the last 48 readings it ranged from 7,984,950 shares (15 September 2025) to 17,117,592 shares (15 January 2025). At the reported average volume of 2.0M shares a day that is 4.6 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/acad" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 9,094,151 | +9.9% | 1,986,923 | 4.58 |
| 2026-09-30 | 8,275,918 | -14.4% | 2,828,484 | 2.93 |
| 2026-09-15 | 9,666,972 | -0.8% | 1,338,393 | 7.22 |
| 2026-08-31 | 9,739,720 | +2.8% | 1,404,719 | 6.93 |
| 2026-08-14 | 9,478,912 | -12.3% | 2,090,088 | 4.54 |
| 2026-07-31 | 10,812,093 | -2.0% | 1,358,749 | 7.96 |
| 2026-07-15 | 11,029,444 | +0.7% | 1,448,908 | 7.61 |
| 2026-06-30 | 10,951,125 | -7.3% | 2,307,777 | 4.75 |
| 2026-06-15 | 11,812,790 | +0.5% | 1,047,620 | 11.28 |
| 2026-05-29 | 11,754,100 | +2.9% | 1,454,891 | 8.08 |
| 2026-05-15 | 11,424,605 | +2.4% | 1,946,766 | 5.87 |
| 2026-04-30 | 11,156,379 | +1.6% | 1,894,956 | 5.89 |
| 2026-04-15 | 10,981,279 | +3.2% | 1,485,801 | 7.39 |
| 2026-03-31 | 10,638,508 | +23.4% | 2,158,686 | 4.93 |
| 2026-03-13 | 8,624,024 | -9.1% | 1,734,865 | 4.97 |
| 2026-02-27 | 9,490,106 | +6.6% | 1,914,400 | 4.96 |
| 2026-02-13 | 8,902,281 | -4.4% | 1,403,357 | 6.34 |
| 2026-01-30 | 9,313,368 | +11.3% | 1,286,570 | 7.24 |
| 2026-01-15 | 8,368,596 | -0.5% | 1,221,254 | 6.85 |
| 2025-12-31 | 8,414,309 | -3.1% | 1,283,730 | 6.55 |
| 2025-12-15 | 8,681,267 | -2.6% | 1,541,868 | 5.63 |
| 2025-11-28 | 8,911,463 | -5.7% | 1,336,272 | 6.67 |
| 2025-11-14 | 9,453,950 | +11.0% | 1,795,206 | 5.27 |
| 2025-10-31 | 8,513,644 | -2.7% | 1,714,407 | 4.97 |
| 2025-10-15 | 8,753,033 | -7.0% | 2,170,142 | 4.03 |
| 2025-09-30 | 9,411,032 | +17.9% | 2,683,307 | 3.51 |
| 2025-09-15 | 7,984,950 | -13.9% | 1,895,926 | 4.21 |
| 2025-08-29 | 9,278,091 | -7.1% | 1,895,249 | 4.90 |
| 2025-08-15 | 9,983,774 | -9.5% | 2,065,648 | 4.83 |
| 2025-07-31 | 11,030,686 | -3.9% | 1,522,484 | 7.25 |
| 2025-07-15 | 11,478,190 | -10.5% | 1,973,081 | 5.82 |
| 2025-06-30 | 12,825,369 | -16.9% | 2,305,581 | 5.56 |
| 2025-06-13 | 15,435,884 | -7.3% | 1,480,513 | 10.43 |
| 2025-05-30 | 16,656,787 | +9.3% | 3,719,881 | 4.48 |
| 2025-05-15 | 15,243,471 | -0.1% | 2,198,051 | 6.93 |
| 2025-04-30 | 15,261,148 | -0.4% | 1,382,741 | 11.04 |
| 2025-04-15 | 15,318,661 | -1.9% | 2,020,451 | 7.58 |
| 2025-03-31 | 15,615,206 | +8.2% | 1,494,767 | 10.45 |
| 2025-03-14 | 14,431,514 | +0.2% | 1,644,594 | 8.78 |
| 2025-02-28 | 14,399,020 | -5.4% | 1,855,271 | 7.76 |
| 2025-02-14 | 15,214,046 | -6.3% | 1,633,375 | 9.31 |
| 2025-01-31 | 16,228,050 | -5.2% | 1,636,223 | 9.92 |
| 2025-01-15 | 17,117,592 | +59.7% | 6,149,383 | 2.78 |
| 2024-12-31 | 10,718,622 | +14.5% | 2,453,888 | 4.37 |
| 2024-12-13 | 9,358,245 | -5.5% | 1,805,677 | 5.18 |
| 2024-11-29 | 9,906,399 | -3.3% | 1,261,245 | 7.85 |
| 2024-11-15 | 10,244,266 | +7.5% | 1,741,149 | 5.88 |
| 2024-10-31 | 9,532,729 | +16.6% | 1,042,851 | 9.14 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of ACAD volume is 46.3%, up 1.5 points over the last five sessions. Over the last 30 readings it ranged from 30.9% (29 October 2026) to 64.5% (13 October 2026). The latest reading is in line with the 30-session average of 47.8%, on 527K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 244K | 527K | 46.3% | 0 |
| 2026-10-30 | 123K | 325K | 37.8% | 1,115 |
| 2026-10-29 | 189K | 612K | 30.9% | 102 |
| 2026-10-28 | 160K | 485K | 33.0% | 220 |
| 2026-10-27 | 166K | 469K | 35.4% | 0 |
| 2026-10-26 | 149K | 332K | 44.8% | 2 |
| 2026-10-23 | 166K | 302K | 55.0% | 0 |
| 2026-10-22 | 228K | 372K | 61.4% | 110 |
| 2026-10-21 | 272K | 485K | 56.0% | 432 |
| 2026-10-20 | 292K | 551K | 53.0% | 8,200 |
| 2026-10-19 | 227K | 486K | 46.7% | 223 |
| 2026-10-16 | 268K | 512K | 52.5% | 0 |
| 2026-10-15 | 187K | 413K | 45.3% | 1,030 |
| 2026-10-14 | 326K | 582K | 56.0% | 0 |
| 2026-10-13 | 526K | 816K | 64.5% | 0 |
| 2026-10-12 | 151K | 397K | 38.0% | 127 |
| 2026-10-09 | 274K | 438K | 62.7% | 7 |
| 2026-10-08 | 278K | 455K | 61.1% | 7,500 |
| 2026-10-07 | 259K | 437K | 59.3% | 0 |
| 2026-10-06 | 305K | 567K | 53.9% | 3,082 |
| 2026-10-05 | 540K | 1.1M | 47.2% | 1,340 |
| 2026-10-02 | 624K | 1.1M | 56.1% | 0 |
| 2026-10-01 | 423K | 872K | 48.5% | 1,010 |
| 2026-09-30 | 438K | 936K | 46.8% | 0 |
| 2026-09-29 | 369K | 1.1M | 33.8% | 0 |
| 2026-09-28 | 536K | 1.5M | 36.6% | 0 |
| 2026-09-25 | 572K | 1.5M | 39.1% | 21,825 |
| 2026-09-24 | 876K | 2.7M | 32.4% | 50,241 |
| 2026-09-23 | 236K | 472K | 50.0% | 400 |
| 2026-09-22 | 227K | 459K | 49.4% | 2,233 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 24 September 2026, the fails-to-deliver balance in ACAD is 6,765 shares, up 5,484 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (29 April 2026) to 125,994 shares (23 January 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-24 | 6,765 | $25.43 | $172K |
| 2026-09-04 | 1,281 | $27.86 | $36K |
| 2026-09-01 | 333 | $28.91 | $10K |
| 2026-08-05 | 7 | $27.15 | $190 |
| 2026-08-04 | 1,565 | $25.61 | $40K |
| 2026-07-20 | 4,182 | $25.60 | $107K |
| 2026-07-16 | 389 | $25.92 | $10K |
| 2026-06-30 | 251 | $25.20 | $6K |
| 2026-06-29 | 18,906 | $25.32 | $479K |
| 2026-06-26 | 381 | $23.72 | $9K |
| 2026-06-15 | 1,202 | $21.09 | $25K |
| 2026-06-08 | 25,079 | $21.56 | $541K |
| 2026-04-29 | 1 | $22.67 | $23 |
| 2026-04-24 | 25,749 | $22.11 | $569K |
| 2026-04-14 | 431 | $21.46 | $9K |
| 2026-03-31 | 11,320 | $21.07 | $239K |
| 2026-03-25 | 88 | $20.96 | $2K |
| 2026-03-23 | 172 | $20.74 | $4K |
| 2026-03-17 | 8 | $21.39 | $171 |
| 2026-02-27 | 14,055 | $24.64 | $346K |
| 2026-02-24 | 2 | $24.73 | $49 |
| 2026-02-06 | 33,067 | $23.46 | $776K |
| 2026-02-02 | 2 | $25.13 | $50 |
| 2026-01-27 | 50 | $26.86 | $1K |
| 2026-01-23 | 125,994 | $27.51 | $3.5M |
| 2025-12-22 | 2,141 | $27.16 | $58K |
| 2025-12-17 | 11,482 | $26.80 | $308K |
| 2025-12-15 | 14,789 | $27.15 | $402K |
| 2025-12-02 | 6,623 | $24.85 | $165K |
| 2025-11-14 | 300 | $23.64 | $7K |
Insider trades
SEC Form 4, newest first. JSONInsiders at ACAD reported 4 open-market sells worth $657K in the last 90 days and no open-market buys. Latest filing: Schneyer Mark C. (EVP, CHIEF FINANCIAL OFFICER) on 2026-10-30.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-30 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3K | $20.88 | $69K | 71K |
| 2026-10-15 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Grant | 7K | $0.00 | $0 | 75K |
| 2026-08-06 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 9K | $29.34 | $273K | 68K |
| 2026-08-06 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 5K | $29.00 | $145K | 77K |
| 2026-08-06 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion | 14K | $17.84 | $255K | 82K |
| 2026-08-05 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 6K | $29.00 | $170K | 68K |
| 2026-08-05 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion | 6K | $17.84 | $104K | 74K |
| 2026-07-30 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | Sell | 50 | $26.17 | $1K | 19K |
| 2026-07-30 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | Sell | 17K | $26.13 | $431K | 19K |
| 2026-07-29 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | Exercise or conversion | 32K | price not stated in the filing | not stated | 36K |
| 2026-06-26 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 11K | $26.08 | $298K | 13K |
| 2026-05-29 | Daly James M | Director | Exercise or conversion | 8K | price not stated in the filing | not stated | 12K |
| 2026-05-29 | GAROFALO ELIZABETH A. | Director | Exercise or conversion | 8K | price not stated in the filing | not stated | 33K |
| 2026-05-29 | Poole Jonathan | Director | Exercise or conversion | 2K | price not stated in the filing | not stated | 2K |
| 2026-05-29 | Brege Laura | Director | Exercise or conversion | 8K | price not stated in the filing | not stated | 23K |
| 2026-05-29 | Ndu Adora | Director | Exercise or conversion | 8K | price not stated in the filing | not stated | 33K |
| 2026-05-29 | HARRIGAN EDMUND | Director | Exercise or conversion | 8K | price not stated in the filing | not stated | 43K |
| 2026-05-29 | Baker Brothers Life Sciences LP | Director,TenPercentOwner | Grant | 19K | $0.00 | $0 | 3.7M |
| 2026-05-29 | BAKER BROS. ADVISORS LP | Director, 10% owner | Grant | 19K | $0.00 | $0 | 3.7M |
| 2026-05-26 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 5K | $21.18 | $114K | 25K |
| 2026-05-04 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 4K | $21.79 | $76K | 66K |
| 2026-05-04 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1K | $21.79 | $29K | 29K |
| 2026-05-01 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion | 7K | price not stated in the filing | not stated | 70K |
| 2026-05-01 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion | 3K | price not stated in the filing | not stated | 30K |
| 2026-04-07 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1K | $22.20 | $23K | 28K |
| 2026-04-07 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3K | $22.20 | $60K | 63K |
| 2026-04-05 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion | 2K | price not stated in the filing | not stated | 29K |
| 2026-04-05 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion | 5K | price not stated in the filing | not stated | 66K |
| 2026-03-26 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 37 | $21.72 | $804 | 60K |
| 2026-03-26 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3K | $21.65 | $69K | 60K |
| 2026-03-26 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 12 | $21.73 | $261 | 27K |
| 2026-03-26 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1K | $21.65 | $24K | 27K |
| 2026-03-25 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 4K | $21.47 | $90K | 57K |
| 2026-03-25 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion | 6K | price not stated in the filing | not stated | 63K |
| 2026-03-25 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion | 2K | price not stated in the filing | not stated | 28K |
| 2026-03-25 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 833 | $21.47 | $18K | 26K |
| 2026-03-25 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | Sell | 3K | $21.47 | $74K | 3K |
| 2026-03-25 | Owen Adams Catherine | Chief Executive Officer | Sell | 12K | $21.47 | $250K | 15K |
| 2026-03-25 | Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC | Sell | 4K | $21.47 | $83K | 11K |
| 2026-03-24 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion | 8K | price not stated in the filing | not stated | 61K |
| 2026-03-24 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion | 2K | price not stated in the filing | not stated | 27K |
| 2026-03-24 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | Exercise or conversion | 7K | price not stated in the filing | not stated | 7K |
| 2026-03-24 | Owen Adams Catherine | Chief Executive Officer | Exercise or conversion | 24K | $0.00 | $0 | 26K |
| 2026-03-24 | Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC | Exercise or conversion | 8K | $0.00 | $0 | 15K |
| 2026-02-09 | Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC | Sell | 7K | $23.38 | $162K | 8K |
| 2026-02-06 | Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC | Exercise or conversion | 13K | $0.00 | $0 | 15K |
| 2025-11-18 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 4K | $23.69 | $97K | 25K |
| 2025-11-18 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 10K | $23.69 | $243K | 53K |
| 2025-11-17 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion | 10K | price not stated in the filing | not stated | 64K |
| 2025-11-17 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion | 4K | price not stated in the filing | not stated | 25K |
| 2025-11-17 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion | 4K | price not stated in the filing | not stated | 29K |
| 2025-11-17 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion | 10K | price not stated in the filing | not stated | 54K |
| 2025-11-10 | Daly James M | Director | Sell | 30K | $22.37 | $671K | 4K |
| 2025-09-15 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3K | $23.65 | $83K | 43K |
| 2025-09-12 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Grant | 7K | $0.00 | $0 | 47K |
| 2025-09-02 | GAROFALO ELIZABETH A. | Director | Sell | 2K | $25.98 | $42K | 25K |
| 2025-08-18 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 22K | $25.18 | $554K | 40K |
| 2025-06-04 | Brege Laura | Director | Sell | 14K | $21.78 | $315K | 15K |
| 2025-05-29 | Baker Bros. Advisors (GP) LLC | Director,TenPercentOwner | Grant | 16K | $0.00 | $0 | 39.4M |
| 2025-05-29 | Brege Laura | Director | Exercise or conversion | 9K | price not stated in the filing | not stated | 30K |
| 2025-05-29 | Daly James M | Director | Exercise or conversion | 9K | price not stated in the filing | not stated | 34K |
| 2025-05-29 | GAROFALO ELIZABETH A. | Director | Exercise or conversion | 9K | price not stated in the filing | not stated | 27K |
| 2025-05-29 | HARRIGAN EDMUND | Director | Exercise or conversion | 9K | price not stated in the filing | not stated | 35K |
| 2025-05-29 | Ndu Adora | Director | Exercise or conversion | 9K | price not stated in the filing | not stated | 25K |
| 2025-05-29 | SOLAND DANIEL B | Director | Exercise or conversion | 9K | price not stated in the filing | not stated | 44K |
| 2025-05-16 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 2K | $25.00 | $50K | 22K |
| 2025-05-16 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 2K | $25.00 | $50K | 62K |
| 2025-05-16 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 2K | $20.00 | $40K | 20K |
| 2025-05-02 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3K | $14.60 | $51K | 63K |
| 2025-05-02 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1K | $14.60 | $19K | 24K |
| 2025-05-01 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion | 7K | price not stated in the filing | not stated | 66K |
| 2025-05-01 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion | 3K | price not stated in the filing | not stated | 25K |
| 2025-04-08 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1K | $14.82 | $15K | 22K |
| 2025-04-08 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3K | $14.82 | $40K | 59K |
| 2025-04-05 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion | 2K | price not stated in the filing | not stated | 23K |
| 2025-04-05 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion | 5K | price not stated in the filing | not stated | 62K |
| 2025-03-26 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3K | $17.05 | $54K | 57K |
| 2025-03-26 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1K | $17.05 | $19K | 21K |
| 2025-03-25 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion | 6K | price not stated in the filing | not stated | 60K |
| 2025-03-25 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion | 2K | price not stated in the filing | not stated | 22K |
| 2025-03-05 | GAROFALO ELIZABETH A. | Director | Sell | 5K | $18.23 | $90K | 18K |
| 2025-02-24 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 773 | $19.96 | $15K | 54K |
| 2025-02-24 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 475 | $19.96 | $9K | 20K |
| 2025-02-23 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion | 1K | price not stated in the filing | not stated | 55K |
| 2025-02-23 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion | 840 | price not stated in the filing | not stated | 21K |
| 2024-11-19 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 10K | $16.81 | $172K | 53K |
| 2024-11-19 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 4K | $16.81 | $68K | 20K |
| 2024-11-19 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Sell | 10K | $16.81 | $174K | 62K |
| 2024-11-17 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Exercise or conversion | 10K | price not stated in the filing | not stated | 63K |
| 2024-11-17 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion | 4K | price not stated in the filing | not stated | 20K |
| 2024-11-17 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion | 10K | price not stated in the filing | not stated | 54K |
| 2024-11-17 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion | 10K | price not stated in the filing | not stated | 64K |
| 2024-11-17 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Exercise or conversion | 4K | price not stated in the filing | not stated | 24K |
| 2024-11-17 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Exercise or conversion | 10K | price not stated in the filing | not stated | 72K |
| 2024-10-12 | Ndu Adora | Director | Exercise or conversion | 4K | price not stated in the filing | not stated | 15K |
| 2024-08-19 | DAVIS STEPHEN | CEO | Sell | 32K | $15.28 | $485K | 187K |
| 2024-08-19 | Teehan Brendan | EVP, COO, HEAD OF COMMERCIAL | Sell | 10K | $15.28 | $146K | 52K |
| 2024-08-19 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 10K | $15.28 | $149K | 44K |
| 2024-08-16 | DAVIS STEPHEN | CEO | Grant | 17K | $0.00 | $0 | 174K |
| 2024-08-16 | DAVIS STEPHEN | CEO | Grant | 45K | $0.00 | $0 | 218K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON4 Form 144 notices on file for ACAD worth $1.2M at the prices reported; 1 in the last 90 days worth $159K. Latest: Schneyer Mark C. filed on 2026-08-05 to sell 5,849 shares ($159K) from 2026-08-05.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-05 | Schneyer Mark C.Officer | 6K | $159K | 0.003% | 2026-08-05 | Piper Sandler & Co Inc |
| 2026-06-26 | Kihara JamesOfficer | 11K | $297K | 0.007% | 2026-06-26 | Piper Sandler & Co Inc |
| 2026-05-26 | JAMES K KIHARAOfficer | 5K | $114K | 0.003% | 2026-05-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-10 | James M DalyDirector | 30K | $671K | 0.018% | 2025-11-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON6 holders report 5% or more of ACAD in their latest filing, 4 on Schedule 13D (active intent). The largest reported stake is Julian C. Baker at 25.4% of the class (43,294,373 shares), filed 2026-02-26 for an event on 2026-02-24.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-07 | 13G | STATE STREET CORPORATIONparent holding company | 9.1M | 5.3% | 2026-06-30 |
| 2026-04-28 | 13G | Vanguard Portfolio Managementinvestment adviser | 8.8M | 5.2% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 9 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-26 | 13D/Ano. 17 | Julian C. Bakerindividual, parent holding company | 43.3M | 25.4% | 2026-02-24 |
| 2026-02-26 | 13D/Ano. 17 | Felix J. Bakerindividual, parent holding company | 43.3M | 25.4% | 2026-02-24 |
| 2026-02-26 | 13D/Ano. 17 | Baker Bros. Advisors LPinvestment adviser, partnership | 43.2M | 25.3% | 2026-02-24 |
| 2026-02-26 | 13D/Ano. 17 | Baker Bros. Advisors (GP) LLCparent holding company, other entity | 43.2M | 25.3% | 2026-02-24 |
| 2026-02-26 | 13D/Ano. 17 | FBB3 LLCother entity | 40K | 0.0% | 2026-02-24 |
| 2025-11-14 | 13G/Ano. 3 | Roderick Wongparent holding company, individual | 7.1M | 4.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 3 | RTW Investments, LPinvestment adviser, partnership | 7.1M | 4.2% | 2025-09-30 |
13F holders
Tracked managers holding ACAD at their latest 13F. JSON9 of the 30 tracked managers held ACAD at their latest 13F, $262.7M in total at quarter-end prices. Point72 Asset Management is the largest at $61.6M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 6 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Point72 Asset Management | 2026-06-30 | 2.4M | $61.6M | 0.07% | -145K |
| Citadel Advisors | 2026-06-30 | 2.2M | $55.2M | 0.01% | +1.6M |
| D. E. Shaw & Co. | 2026-06-30 | 1.7M | $43.0M | 0.02% | +968K |
| Renaissance Technologies | 2026-06-30 | 1.3M | $32.4M | 0.04% | -442K |
| Two Sigma Investments | 2026-06-30 | 927K | $23.5M | 0.02% | +152K |
| Fisher Asset Management | 2026-06-30 | 699K | $17.7M | 0.01% | -34K |
| Millennium Management | 2026-06-30 | 590K | $14.9M | 0.01% | -116K |
| AQR Capital Management | 2026-06-30 | 523K | $13.2M | 0.00% | -5K |
| Bridgewater Associates | 2026-06-30 | 50K | $1.3M | 0.01% | -92K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Acadia Pharmaceuticals reported revenue of $308.0M, up 16.4% from the same quarter a year earlier, and net income of $31.5M (0.18 diluted EPS). In FY 2025 it generated $109.8M of operating cash flow.
- Cash
- $385.0M
- Equity
- $1.31B
- Total assets
- $1.74B
- Shares outstanding
- 172,305,518
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $308.0M | $31.5M | 10.2% | 0.18 |
| Q1 FY 2026 | 2026-03-31 | $268.1M | $3.6M | 1.4% | 0.02 |
| Q4 FY 2025derived | 2025-12-31 | $284.0M | $273.6M | 96.3% | n/a |
| Q3 FY 2025 | 2025-09-30 | $278.6M | $71.8M | 25.8% | 0.42 |
| Q2 FY 2025 | 2025-06-30 | $264.6M | $26.7M | 10.1% | 0.16 |
| Q1 FY 2025 | 2025-03-31 | $244.3M | $19.0M | 7.8% | 0.11 |
| Q4 FY 2024derived | 2024-12-31 | $259.6M | $143.7M | 55.4% | n/a |
| Q3 FY 2024 | 2024-09-30 | $250.4M | $32.8M | 13.1% | 0.20 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $1.07B | $391.0M | $109.8M | $4.7M | n/a | n/a |
| FY 2024 | 2024-12-31 | $957.8M | $226.5M | $157.7M | $523K | n/a | n/a |
| FY 2023 | 2023-12-31 | $726.4M | -$61.3M | $16.7M | $50K | n/a | n/a |
| FY 2022 | 2022-12-31 | $517.2M | -$216.0M | -$114.0M | $0 | n/a | n/a |
| FY 2021 | 2021-12-31 | $484.1M | -$167.9M | -$125.7M | $1.1M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-28 from the cover page.
What this page is
Acadia Pharmaceuticals in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Acadia Pharmaceuticals (ACAD), SEC CIK 1070494, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-24.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-08-05.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-07.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-04.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-30.JSON and CSV
- Company record
- EDGAR filing index for CIK 1070494Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of ACAD is sold short?
9,094,151 shares were held short at the 2026-10-15 settlement, 4.6 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ACAD's daily short volume?
On 2026-11-02, 244,390 of the 527,404 ACAD shares reported to FINRA were sold short, 46.3% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ACAD have fails to deliver?
The SEC's latest file shows 6,765 ACAD shares failed to deliver at settlement 2026-09-24. Fails are reported per settlement date and published twice a month with a lag.
Are ACAD insiders buying or selling?
Insiders at ACAD reported 4 open-market sells worth $657K in the last 90 days and no open-market buys. Latest filing: Schneyer Mark C. (EVP, CHIEF FINANCIAL OFFICER) on 2026-10-30.
Have ACAD insiders filed to sell?
4 Form 144 notices on file for ACAD worth $1.2M at the prices reported; 1 in the last 90 days worth $159K. Latest: Schneyer Mark C. filed on 2026-08-05 to sell 5,849 shares ($159K) from 2026-08-05.
Who owns 5% or more of ACAD?
6 holders report 5% or more of ACAD in their latest filing, 4 on Schedule 13D (active intent). The largest reported stake is Julian C. Baker at 25.4% of the class (43,294,373 shares), filed 2026-02-26 for an event on 2026-02-24.
What did ACAD report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Acadia Pharmaceuticals reported revenue of $308.0M, up 16.4% from the same quarter a year earlier, and net income of $31.5M (0.18 diluted EPS). In FY 2025 it generated $109.8M of operating cash flow.
Which tracked 13F managers own ACAD?
9 of the 30 tracked 13F managers held ACAD shares at their latest filing, $262.7M in all. The largest: Steve Cohen's Point72 Asset Management (2.4M shares, $61.6M), Ken Griffin's Citadel Advisors (2.2M shares, $55.2M), D. E. Shaw & Co. (1.7M shares, $43.0M), Renaissance Technologies (1.3M shares, $32.4M), Two Sigma Investments (927K shares, $23.5M), Ken Fisher's Fisher Asset Management (699K shares, $17.7M). The table above lists all 9.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.